Startup Spotlight: Kernel’s non-invasive brain recording

By William Smith
Kernel is a Los Angeles, California-based startup developing non-invasive brain recording technology...

Kernel is a Los Angeles, California-based startup developing non-invasive brain recording technology.

The company’s neuroscience as a service (NaaS) platform is commercially available, enabling customers to access brain imaging devices remotely.

Its brain recording technologies are known as Flow and Flux. The latter detects magnetic fields generated by neural activity, while Flow measures blood flow as representative of neural activity.

It says its products overcome the limitations of current brain imaging hardware, which can be expensive, bulky or require surgery.

Kernel hopes to create an ecosystem for human improvement based on what it calls a “neurome”, analogous to a person’s genome.

Since its foundation in 2016, the company has raised a significant sum. Its latest Series C, which it said was its first outside funding round, saw the company raise $53mn from lead investor General Catalyst, alongside Tiny Blue Dot, Manta Ray Ventures, Khosla Ventures and Eldridge.

In a press release, the company’s CEO and founder Bryan Johnson said: “Mainframes became PCs and then smartphones. The $1B genome became the $1,000 genome. The brain and mind are next. 

“We live in a data-illuminated world, but the user manuals for our brains have no diagnostic or useful numbers, leaving us with no option but to describe and characterize cognition using hunches.” Johnson continued, “Imagine a cardiologist asking you how your heart is doing based upon your hunches, without cholesterol or blood pressure.

“If we can quantify thoughts and emotions, conscious and subconscious, a new era of understanding, wellness, and human improvement will emerge.”

The company said it would use the investment to accelerate on-demand access to its products, developing its technology further.

“The vision fueling Kernel is one of the most audacious imaginable.” said Quentin Clark, General Partner, General Catalyst. “But that ambition has a passionate and committed founder and team, and pragmatic engineering work to back it up. Kernel’s engineering accomplishments have the potential to enable more neuroscience progress in the next few years than has been accomplished in the last few decades.”

Share

Featured Articles

Healthcare business roundup: Eli Lilly, Novo Nordisk, Aspen

Eli Lilly's experimental cardiovascular drug ‘promising’; Aspen Pharmacare to manufacture mpox vaccines; Novo Nordisk says Ozempic shortage ‘worsening’

Global Health Funding 'Facing Post-Pandemic Challenges'

IHME report highlights shifting priorities and economic pressures affecting global health financing, despite increase in funding since pre-COVID levels

The Merck Group: Pharma's History & Innovation in India

Welcome back to part two of our exploration of The Merck Group's history and investment in China and India, with this part focusing on innovation in India

How CVS Health is Rising to the Omnichannel Challenge

Procurement & Supply Chain

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Procurement & Supply Chain

Healthcare Digital Transformations Stymied by Data Silos

Digital Healthcare